Add as a preferred source on GoogleBioventus Lowers 2026 Revenue Outlook to $590 Million-$595 Million
The company reaffirmed adjusted EPS guidance of $0.75 to $0.79 and expects mid-single-digit revenue growth in the fourth quarter.
Bioventus Inc. lowered its 2026 revenue outlook to $590 million to $595 million, with management citing weaker-than-expected Bone Graft Substitutes performance and the timing of newly onboarded representatives.
The company reaffirmed adjusted EPS guidance of $0.75 to $0.79. It expects mid-single-digit revenue growth in the fourth quarter.
In the third quarter, Pain Treatments grew 6%, while revenue excluding Bone Graft Substitutes also rose 6%. Bioventus adjusted its cash-from-operations guidance to $84 million to $89 million and expects net leverage below 1.5x by year-end.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.